Previous studies have shown that combining appropriate chemotherapy regimens with PD‐1/PD‐L1 blockade and optimizing the tumor immune microenvironment can enhance the antitumor immune efficacy of PD‐1/PD‐L1 inhibitors [19]. This evidence concerns the gene CD274 and neoplasm.